Article Abstract

Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer

Authors: Gustavo Werutsky, Tomás Reinert, André Poisl Fay


The ALTERNATIVE trial has shown progression-free survival (PFS) benefit with the addition of lapatinib (LAP) to trastuzumab (TRAS) and an aromatase inhibitor (AI) among postmenopausal patients with hormone receptor (HR), human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (MBC). These findings were reported by Johnston et al. in the Journal of Clinical Oncology (1).